Based on the information presented above, it is reasonable to believe that diosgenin may act against breast cancer by reducing glucose utilization, invasion, and metastasis via the surface protein IGF1R. Furthermore, it may limit cancer cell proliferation by acting on another surface protein, PDGFRB. In addition, the diosgenin may also act over the MDM2 and prevent the cancer cell to escape the p53 surveillance in the cytoplasm. This evidence concerns the gene TP53 and breast carcinoma.